James R. Empfield's most recent trade in Xenon Pharmaceuticals Inc was a trade of 65,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 11, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 11 Mar 2024 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 10 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 45,000 | 75,000 (0%) | 0% | 4.8 | 213,750 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 35,868 | 31,875 (0%) | 0% | 38.1 | 1,365,853 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 21,875 | 10,000 (0%) | 0% | 38.7 | 846,125 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 20,000 | 30,000 (0%) | 0% | 3.1 | 62,000 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Aug 2022 | 7,257 | 67,743 (0%) | 0% | 38.0 | 275,911 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 10 Mar 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 40,000 | 51,805 (0%) | 0% | 6.8 | 270,400 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 31,048 | 10,000 (0%) | 0% | 30.5 | 948,206 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 25,000 | 35,000 (0%) | 0% | 8.4 | 210,000 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 18,315 | 10,000 (0%) | 0% | 30.8 | 563,919 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 8,952 | 42,853 (0%) | 0% | 30.2 | 270,619 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 6,685 | 28,315 (0%) | 0% | 31.4 | 210,043 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 2,500 | 12,500 (0%) | 0% | 8.4 | 21,000 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 2,500 | 0 | - | - | Stock Option (Right to Buy) | ||
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 1,805 | 41,048 (0%) | 0% | 30.6 | 55,269 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 04 Mar 2022 | 695 | 11,805 (0%) | 0% | 30.2 | 21,010 | Common Shares | |
| Xenon Pharmaceuticals Inc | James R. Empfield | EVP, Drug Discovery | 12 Mar 2021 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) |